Last updated: February 23, 2026
What is the Drug?
NDC 50474-0801 refers to a specific formulation within the National Drug Code (NDC) system. It is identified as Rybelsus (semaglutide), an oral glucagon-like peptide-1 (GLP-1) receptor agonist marketed for type 2 diabetes management.
Market Size and Investor Context
The global diabetes medication market was valued at approximately USD 63 billion in 2022. The GLP-1 receptor agonist segment grew at a compound annual growth rate (CAGR) of around 13% from 2018 to 2022, driven by increased adoption of oral and injectable therapies.
Rybelsus holds a significant position within this segment. As of Q4 2022, it accounted for roughly 15% of the oral GLP-1 market, translating to an estimated sales volume of USD 1.2 billion globally.
Competitive Landscape
Major competitors include injectable GLP-1 drugs such as:
- Victoza (liraglutide) — Novo Nordisk
- Trulicity (dulaglutide) — Eli Lilly
- Ozempic (semaglutide) — Novo Nordisk
Oral GLP-1 therapies are a relatively new segment, with Rybelsus launched in 2019. The drug's unique oral formulation distinguishes it from injectables, which offer clinical advantages but face patient adherence challenges.
Current Pricing and Reimbursement
In the U.S., the average wholesale price (AWP) for Rybelsus ranges from USD 810 to USD 900 per 30-day supply. Insurance coverage and PBM negotiations typically reduce net prices, with patients often facing copays ranging from USD 20 to USD 50.
In European markets, list prices are approximately EUR 580–650 per month. Reimbursement varies by country but generally covers a significant portion of the drug's cost for eligible patients.
Price Projections
Short-Term (Next 2 Years)
- Price stability: Given existing market dynamics, average prices are expected to remain within the current range, considering contractual rebates and discounts.
- Potential decrease: Payers and PBMs may negotiate further discounts, possibly reducing net prices by 10–15% over this period.
Medium-Term (Next 3–5 Years)
- Market penetration: Increased adoption due to expanded indications (e.g., obesity, cardiovascular risk management) could support higher volume sales.
- Pricing leverage: Growing competition from biosimilar sevelamer and future oral GLP-1 entrants could pressure list prices downward by 10–20%.
Long-Term (Beyond 5 Years)
- Biosimilar presence: Entry of biosimilars and alternative oral GLP-1 products may lead to substantial price erosion.
- Regulatory and policy shifts: Increased emphasis on cost-effectiveness may further push prices downward, potentially by 30% or more.
Regulatory and Policy Influences
- The FDA approval process for generics and biosimilars impacts future pricing.
- Value-based pricing initiatives can influence reimbursement rates.
- Patent expirations for key formulations could encourage market entry.
Key Drivers
- Increasing diabetic prevalence, projected to reach 700 million globally by 2045.
- Growing awareness of the convenience of oral GLP-1 therapies.
- Cost containment policies from payers and healthcare systems.
Summary Table
| Factor |
Current Status |
Projection |
| Price Range (U.S.) |
USD 810–USD 900 per month |
Stable to slight decrease (10–15%) |
| Market Share (oral GLP-1) |
Approx. 15% (Q4 2022) |
Increase with expanding indications |
| Competition |
Injectable GLP-1s, limited oral options |
More oral competitors entering over 3–5 years |
| Biosimilar Entry |
None yet for semaglutide (oral formulation) |
Possible biosimilar development beyond 2025 |
Key Takeaways
- NDC 50474-0801 (Rybelsus) maintains a dominant position within the oral GLP-1 class, though face mounting competition.
- Short-term pricing is expected to remain stable; medium to long-term price erosion likely due to biosimilars, biosynthetic alternatives, and payer pressure.
- Market growth driven by increasing diabetes prevalence and expanded indications can offset some price erosion.
- Net prices will depend on negotiations, reimbursement policies, and regulatory developments in major markets.
FAQs
Q1: Will Rybelsus's price increase in the next two years?
A1: Unlikely. Market stability and payer negotiations may prevent significant increases; slight decreases are possible.
Q2: How might biosimilar entry affect Rybelsus prices?
A2: Biosimilar development may lead to price reductions of 20–30% over 5–7 years, depending on regulatory approvals and market adoption.
Q3: Are there pricing differences between regions?
A3: Yes. U.S. prices tend to be higher than European list prices, but net prices vary due to rebates, payer negotiations, and healthcare policies.
Q4: What factors could accelerate price decreases?
A4: Increased competition, patent expiration, and policy shifts favoring cost containment.
Q5: How does Rybelsus's market share impact its revenue prospects?
A5: Growing adoption due to efficacy and convenience enhances revenue, even if unit prices decline.
References
- MarketWatch. (2023). Diabetes drugs market size and growth. Retrieved from https://www.marketwatch.com/
- IQVIA. (2022). Global use of injectable and oral GLP-1 receptor agonists. IQVIA Institute Report.
- FDA. (2022). Guidance on biosimilar product development.
- European Medicines Agency. (2022). Reimbursement policies for diabetes treatments.
- GoodRx. (2023). Diabetes drug prices. Retrieved from https://www.goodrx.com/
[1] World Health Organization. (2022). Diabetes Fact Sheet. Retrieved from https://www.who.int/
